In vitro evaluation of combined temozolomide and radiotherapy using XRays and high-linear energy transfer radiation for glioblastoma

Radiation Research

Volumn 177, Issue 5, 2012, Pages 651-662

  Barazzuol, Lara ^a   Jena, Raj ^a,c   Burnet, Neil G ^a,c   Jeynes, Jonathan C G ^a   Merchant, Michael J ^a   Kirkby, Karen J ^a   Kirkby, Norman F ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ALPHA RADIATION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RADIOTHERAPY; DRUG MECHANISM; GLIOBLASTOMA; HIGH LINEAR ENERGY TRANSFER RADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; X RAY;

ALPHA PARTICLES; CELL DIVISION; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; GLIOBLASTOMA; HUMANS; LINEAR ENERGY TRANSFER; NEOPLASM PROTEINS; PARTICLE ACCELERATORS; PHOTONS; PROMOTER REGIONS, GENETIC; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 84861409519     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2803.1     Document Type: Article

References (44)

1. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71(8): 2585-97. (Pubitemid 23100496)
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96. (Pubitemid 40349501)
3. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: Mechanism of action and related DNA repair systems. Pharmacol Res 2007; 56(4):275-87. (Pubitemid 47488901)
4. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Eng J Med 2005; 352(10): 997-1003. (Pubitemid 40349502)
5. von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011 Jan; 21(1):74-87.
6. Kovalchuk O, Baulch JE. Epigenetic changes and nontargeted radiation effects-is there a link? Environ Mol Mutagen 2008; 49(1):16-25. (Pubitemid 351293009)
7. Goetz W, Morgan MN, Baulch JE. The effect of radiation quality on genomic DNA methylation profiles in irradiated human cell lines. Radiat Res 2011; 175(5):575-87.
8. Kovalchuk O, Burke P, Besplug J, Slovack M, Filkowski J, Pogribny I. Methylation changes in muscle and liver tissues of male and female mice exposed to acute and chronic low-dose X-ray-irradiation. Mutat Res 2004; 548(1-2):75-84. (Pubitemid 38446883)
9. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10(5):459-66.
10. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5(10):1725-31. (Pubitemid 10187518)
11. Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006; 65(2):499-508.
12. Tobias CA, Blakely EA, Alpen EL, Castro JR, Ainsworth EJ, Curtis SB, et al. Molecular and cellular radiobiology of heavy ions. Int J Radiat Oncol Biol Phys 1982; 8(12):2109-20. (Pubitemid 13180415)
13. 20Ne-ion beams. Radiat Res 2000; 154(5):485-96.
14. Stone RS. Neutron therapy and specific ionization. Am J Roentgenol Radium Ther 1948; 59(6):771-85.
15. Wilson R. Radiological use of fast protons. Radiology 1946; 47(5): 487-91.
16. Castro JR, Saunders WM, Austin-Seymour MM, Woodruff KH, Gauger G, Chen GT, et al. A phase I-II trial of heavy charged particle irradiation of malignant glioma of the brain: a Northern California Oncology Group Study. Int J Radiat Oncol Biol Phys 1985; 11(10):1795-800. (Pubitemid 16224017)
17. Fitzek MM, Thornton AF, Rabinov JD, Lev MH, Pardo FS, Munzenrider JE, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multi-forme: results of a phase II prospective trial. J Neurosurg 1999; 91(2):251-60.
18. Mizoe JE, Tsujii H, Hasegawa A, Yanagi T, Takagi R, Kamada T, et al. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69(2):390-6. (Pubitemid 47380082)
19. Maucort-Boulch D, Baron MH, Pommier P, Weber DC, Mizoe JE, Rochat J, et al. Rationale for carbon ion therapy in high-grade glioma based on a review and a meta-analysis of neutron beam trials. Cancer Radiother 2010; 14(1):34-41.
20. Benzina S, Debomy F, Bergerat JP, Denis JM, Gueulette J, Dufour P, et al. The cytotoxicity of high-linear energy transfer radiation is reinforced by oxaliplatin in human glioblastoma cells. Cancer Lett 2007; 254(1):54-62. (Pubitemid 47058803)
21. Combs SE, Bohl J, Elsasser T, Weber KJ, Schulz-Ertner D, Debus J, et al. Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. Int J Radiat Biol 2009; 85(2):126-36.
22. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008; 14(3):931-8. (Pubitemid 351231178)
23. Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, Short SC. Cytotoxic effects of temozolomide and radiation are additive-and schedule-dependent. Int J Radiat Oncol Biol Phys 2009; 75(5): 1511-9.
24. Silari M. Applications of particle accelerators in medicine. Radiat Prot Dosimetry 2011; 146(4):440-50.
25. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006; 96(3):766-76.
26. Kirkby KJ, Grime GW, Webb RP, Kirkby NF, Folkard M, Prise K, et al. A scanning focussed vertical ion nanobeam: A new UK facility for cell irradiation and analysis. Nucl Instrum Meth B 2007; 260:97-100. (Pubitemid 46874642)
27. Ziegler JF, Ziegler MD, Biersack JP. SRIM-The stopping and range of ions in matter (2010). Nucl Instrum Meth B 2010; 268:1818-23.
28. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10:3728-36. (Pubitemid 38697606)
29. Sakata K, Someya M, Matsumoto Y, Hareyama M. Ability to repair DNA double-strand breaks related to cancer susceptibility and radiosensitivity. Radiat Med 2007; 25(9):433-8. (Pubitemid 351928005)
30. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23(1):35-61. (Pubitemid 27273454)
31. Trog D, Moenkemann H, Haertel N, Schüller H, Golubnitschaja O. Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment. Amino Acids 2005; 28(2):213-9.
32. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001; 61(5):1957-63. (Pubitemid 32692013)
33. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997; 8(1):92-7. (Pubitemid 27064756)
34. Gerweck LE, Kozin SV. Relative biological effectiveness of proton beams in clinical therapy. Radiother Oncol 1999; 50(2): 135-42. (Pubitemid 29155537)
35. Takahashi A, Ohnishi K, Tsuji K, Matsumoto H, Aoki H, Wang X, et al. WAF1 accumulation by carbon-ion beam and alpha-particle irradiation in human glioblastoma cultured cells. Int J Radiat Biol 2000; 76(3):335-41. (Pubitemid 30137740)
36. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003; 3(2):117-29. (Pubitemid 37328879)
37. Iwadate Y, Mizoe J, Osaka Y, Yamaura A, Tsujii H. High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53. Int J Radiat Oncol Biol Phys 2001; 50(3):803-8. (Pubitemid 32515335)
38. Tsuboi K, Moritake T, Tsuchida Y, Tokuuye K, Matsumura A, Ando K. Cell cycle checkpoint and apoptosis induction in glioblastoma cells and fibroblasts irradiated with carbon beam. J Radiat Res 2007; 48(4):317-25. (Pubitemid 47105603)
39. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006; 12(15):4738-46. (Pubitemid 44297828)
40. Short SC, Martindale C, Bourne S, Brand G, Woodcock M, Johnston P. DNA repair after irradiation in glioma cells and normal human astrocytes. Neuro Oncol 2007; 9(4):404-11.
41. Leatherbarrow EL, Harper JV, Cucinotta FA, O'Neill P. Induction and quantification of c-H2AX foci following low and high LET-irradiation. Int J Radiat Biol 2006; 82:111-8.
42. Kegel P, Riballo E, Kühne M, Jeggo PA, Löbrich M. X-irradiation of cells on glass slides has a dose doubling impact. DNA Repair 2007; 6(11):1692-7. (Pubitemid 47610758)
43. Antoccia A, Sgura A, Berardinelli F, Cavinato M, Cherubini R, Gerardi S, et al. Cell cycle perturbations and genotoxic effects in human primary fibroblasts induced by low-energy protons and X/gamma-rays. J Radiat Res 2009; 50:457-68.
44. Iliakis G, Wang H, Perrault AR, Boecker W, Rosidi B, Windhofer F, et al. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res 2004; 104(1-4):14-20. (Pubitemid 38721048)